SpectraCure AB Cash Flow Conversion Efficiency
SpectraCure AB cash flow conversion efficiency. Based on the latest financial reports, SpectraCure AB (SPEC) has a cash flow conversion efficiency ratio of -0.048x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-4.48 Million ≈ $-482.55K USD) by net assets (Skr93.55 Million ≈ $10.07 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of SpectraCure AB (2014–2025)
Cash flow conversion efficiency of SpectraCure AB from 2014 to 2025. This chart illustrates how SpectraCure AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View SpectraCure AB (SPEC) share price today for real-time trading data and today's change.
SpectraCure AB Cash Flow Conversion Ratio Explained
SpectraCure AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
SpectraCure AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SpectraCure AB ranked by their cash flow conversion efficiency. Also see SPEC company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
M.T.I Wireless Edge Ltd
LSE:MWE
|
-0.003x |
|
Lilium NV
NASDAQ:LILM
|
0.005x |
|
Magic Empire Global Limited
NASDAQ:MEGL
|
-0.038x |
|
Sunindo Adipersada Tbk Pt
JK:TOYS
|
-0.001x |
|
MEMIONTEC HOLDINGS LTD
F:8900
|
N/A |
|
IMAGE POWER S.A. ZY -10
F:7UQ
|
0.628x |
|
Infinitum Copper Corp
V:INFI
|
-0.132x |
|
Creo Medical Group PLC
LSE:CREO
|
-0.684x |
Annual Cash Flow Conversion Efficiency for SpectraCure AB (2014–2025)
The table below shows the annual cash flow conversion efficiency of SpectraCure AB from 2014 to 2025. Review SpectraCure AB free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr93.55 Million ≈ $10.07 Million |
Skr-24.03 Million ≈ $-2.59 Million |
-0.257x | -25.74% |
| 2024-12-31 | Skr106.86 Million ≈ $11.50 Million |
Skr-21.83 Million ≈ $-2.35 Million |
-0.204x | -41.99% |
| 2023-12-31 | Skr129.86 Million ≈ $13.97 Million |
Skr-18.68 Million ≈ $-2.01 Million |
-0.144x | +5.84% |
| 2022-12-31 | Skr150.30 Million ≈ $16.17 Million |
Skr-22.96 Million ≈ $-2.47 Million |
-0.153x | -44.27% |
| 2021-12-31 | Skr175.68 Million ≈ $18.91 Million |
Skr-18.60 Million ≈ $-2.00 Million |
-0.106x | -122.07% |
| 2020-12-31 | Skr197.22 Million ≈ $21.22 Million |
Skr-9.40 Million ≈ $-1.01 Million |
-0.048x | +58.37% |
| 2019-12-31 | Skr87.78 Million ≈ $9.45 Million |
Skr-10.05 Million ≈ $-1.08 Million |
-0.115x | +17.12% |
| 2018-12-31 | Skr64.92 Million ≈ $6.99 Million |
Skr-8.97 Million ≈ $-965.53K |
-0.138x | -129.30% |
| 2017-12-31 | Skr13.41 Million ≈ $1.44 Million |
Skr6.33 Million ≈ $680.77K |
0.472x | +153.22% |
| 2016-12-31 | Skr22.11 Million ≈ $2.38 Million |
Skr-19.60 Million ≈ $-2.11 Million |
-0.886x | -19.15% |
| 2015-12-31 | Skr13.06 Million ≈ $1.41 Million |
Skr-9.71 Million ≈ $-1.05 Million |
-0.744x | -482.81% |
| 2014-12-31 | Skr-3.11 Million ≈ $-334.73K |
Skr-604.49K ≈ $-65.05K |
0.194x | -- |
About SpectraCure AB
SpectraCure AB (publ) engages in the development of cancer treatment system in Sweden. It develops Q-PRO, a laser unit; IDOSE software platform, which calculates the optimal laser light dose and placement of the optical fibers; and disposable items comprising needles, optical fibers, and light-sensitive medication. The company was incorporated in 2003 and is based in Lund, Sweden.